MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 582056 | Name: Decitabine mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Decitabine mesylate is an azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.

Chemical Structure

Decitabine mesylate
Decitabine mesylate
CAS#879492-57-6

Theoretical Analysis

MedKoo Cat#: 582056

Name: Decitabine mesylate

CAS#: 879492-57-6

Chemical Formula: C9H14N4O6S

Exact Mass: 306.0600

Molecular Weight: 306.29

Elemental Analysis: C, 35.29; H, 4.61; N, 18.29; O, 31.34; S, 10.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Decitabine mesylate; decitabine mesilate; decitabine; dacogen; UNII-6U3LPL9PRN; 6U3LPL9PRN; decitabine mesylate; SCHEMBL3394791.
IUPAC/Chemical Name
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-, monomethanesulfonate
InChi Key
PVJZOLVUFIDNLJ-RRKCRQDMSA-N
InChi Code
InChI=1S/C9H14N4O6S/c1-20(16,17)19-5-2-7(18-6(5)3-14)13-4-11-8(10)12-9(13)15/h4-7,14H,2-3H2,1H3,(H2,10,12,15)/t5-,6+,7+/m0/s1
SMILES Code
O=C1N([C@H]2C[C@H](OS(C)(=O)=O)[C@@H](CO)O2)C=NC(N)=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 306.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):381-390. doi: 10.1182/hematology.2019000042. PubMed PMID: 31808894. 2: Li J, Su X, Dai L, Chen N, Fang C, Dong Z, Fu J, Yu Y, Wang W, Zhang H, Wang H, Ji Y, Liu Y, Cheng L, Shi G, Zhang S, Yang Y, Deng H. Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer. Carcinogenesis. 2019 Dec 5. pii: bgz199. doi: 10.1093/carcin/bgz199. [Epub ahead of print] PubMed PMID: 31802101. 3: Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H; DECIDER Study Team. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053. [Epub ahead of print] PubMed PMID: 31794324. 4: Petralia MC, Mazzon E, Basile MS, Cutuli M, Di Marco R, Scandurra F, Saraceno A, Fagone P, Nicoletti F, Mangano K. Effects of Treatment with the Hypomethylating Agent 5-aza-2'-deoxycytidine in Murine Type II Collagen-Induced Arthritis. Pharmaceuticals (Basel). 2019 Nov 27;12(4). pii: E174. doi: 10.3390/ph12040174. PubMed PMID: 31783688. 5: Steensma DP. Does early diagnosis and treatment of myelodysplastic syndromes make a difference? Best Pract Res Clin Haematol. 2019 Dec;32(4):101099. doi: 10.1016/j.beha.2019.101099. Epub 2019 Oct 18. Review. PubMed PMID: 31779983. 6: Ai H, Wei XD, Yin QS, Mi RH, Chen L, Wang Q, Song YP. [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome]. Zhonghua Nei Ke Za Zhi. 2019 Dec 1;58(12):908-910. doi: 10.3760/cma.j.issn.0578-1426.2019.12.008. Chinese. PubMed PMID: 31775455. 7: Abou Najem S, Khawaja G, Hodroj MH, Babikian P, Rizk S. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells. Cells. 2019 Nov 21;8(12). pii: E1480. doi: 10.3390/cells8121480. PubMed PMID: 31766421. 8: Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell Melanoma Res. 2019 Nov 23. doi: 10.1111/pcmr.12849. [Epub ahead of print] PubMed PMID: 31758842. 9: Jayaraman A, Jayaraman S. DNA hypermethylation does not negatively impact the transcription of the TNF-α gene in an acute T-cell leukemia. Epigenomics. 2019 Dec;11(16):1753-1763. doi: 10.2217/epi-2019-0015. Epub 2019 Nov 22. PubMed PMID: 31755306. 10: Elsharkawi I, Parambath D, Saber-Ayad M, Khan AA, El-Serafi AT. Exploring the effect of epigenetic modifiers on developing insulin-secreting cells. Hum Cell. 2019 Nov 21. doi: 10.1007/s13577-019-00292-y. [Epub ahead of print] PubMed PMID: 31755075. 11: Molica M, Breccia M, Capria S, Trisolini S, Foa R, Jabbour E, Kadia TM. The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leuk Lymphoma. 2019 Nov 22:1-10. doi: 10.1080/10428194.2019.1672060. [Epub ahead of print] PubMed PMID: 31752577. 12: Grieve S, Wajnberg G, Lees M, Chacko S, Weir J, Crapoulet N, Reiman T. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC. Blood Adv. 2019 Nov 26;3(22):3613-3625. doi: 10.1182/bloodadvances.2019000374. PubMed PMID: 31743393; PubMed Central PMCID: PMC6880893. 13: Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management. Am J Hematol. 2019 Nov 17. doi: 10.1002/ajh.25684. [Epub ahead of print] PubMed PMID: 31736132. 14: Awada H, Mahfouz RZ, Kishtagari A, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, Maciejewski JP, Saunthararajah Y. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. Br J Haematol. 2019 Nov 17. doi: 10.1111/bjh.16281. [Epub ahead of print] PubMed PMID: 31736067. 15: Das A, Alshareef M, Henderson F Jr, Martinez Santos JL, Vandergrift WA 3rd, Lindhorst SM, Varma AK, Infinger L, Patel SJ, Cachia D. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth. Clin Transl Oncol. 2019 Nov 15. doi: 10.1007/s12094-019-02240-6. [Epub ahead of print] PubMed PMID: 31732915. 16: Liu K, Dong F, Gao H, Guo Y, Li H, Yang F, Zhao P, Dai Y, Wang J, Zhou W, Zou C. Promoter hypermethylation of the CFTR gene as a novel diagnostic and prognostic marker of breast cancer. Cell Biol Int. 2019 Nov 13. doi: 10.1002/cbin.11260. [Epub ahead of print] PubMed PMID: 31721358. 17: He Z, Zhang S, Ma D, Fang Q, Yang L, Shen S, Chen Y, Ren L, Wang J. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia. J Transl Med. 2019 Nov 11;17(1):366. doi: 10.1186/s12967-019-2115-9. PubMed PMID: 31711520; PubMed Central PMCID: PMC6849246. 18: Sergeeva O, Kepe V, Zhang Y, Miller-Atkins GA, Keynon JD, Iyer R, Sexton S, Awadallah A, Xin W, Saunthararajah Y, Chan ER, Lee Z. [(18)F] Clofarabine for PET Imaging of Hepatocellular Carcinoma. Cancers (Basel). 2019 Nov 7;11(11). pii: E1748. doi: 10.3390/cancers11111748. PubMed PMID: 31703407. 19: Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019 Oct 23;10:2040620719882822. doi: 10.1177/2040620719882822. eCollection 2019. Review. PubMed PMID: 31692757; PubMed Central PMCID: PMC6811760. 20: Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00119. Epub 2019 Sep 20. PubMed PMID: 31663066; PubMed Central PMCID: PMC6818517.

View History

Trimetoquinol HCl hydrate

Trimetoquinol HCl hydrate